scispace - formally typeset
T

Timothy S. Kern

Researcher at University of California, Irvine

Publications -  242
Citations -  20970

Timothy S. Kern is an academic researcher from University of California, Irvine. The author has contributed to research in topics: Diabetic retinopathy & Retinal. The author has an hindex of 70, co-authored 232 publications receiving 19071 citations. Previous affiliations of Timothy S. Kern include Veterans Health Administration & Case Western Reserve University.

Papers
More filters
Journal ArticleDOI

A central role for inflammation in the pathogenesis of diabetic retinopathy

TL;DR: It is shown that chronic, low‐grade subclinical inflammation is responsible for many of the signature vascular lesions of diabetic retinopathy, highlighting the central and causal role of adherent leukocytes in the pathogenesis of diabetes.
Journal ArticleDOI

Amelioration of Vascular Dysfunctions in Diabetic Rats by an Oral PKC β Inhibitor

TL;DR: When administered orally, LY333531 ameliorated the glomerular filtration rate, albumin excretion rate, and retinal circulation in diabetic rats in a dose-responsive manner, in parallel with its inhibition of PKC activities.
Journal ArticleDOI

Inflammation in diabetic retinopathy.

TL;DR: The inflammatory mediators and their relationship to early and late DR are reviewed, and the potential of anti-inflammatory approaches to inhibit development of different stages of the retinopathy is discussed.
Journal ArticleDOI

Accelerated death of retinal microvascular cells in human and experimental diabetic retinopathy.

TL;DR: Findings indicate that diabetes and galactosemia lead to accelerated death in situ of both retinal pericytes and endothelial cells; the event is specific for vascular cells; it precedes histological evidence of retinopathy; and it can be induced by isolated hyperhexosemia.
Journal ArticleDOI

Contributions of Inflammatory Processes to the Development of the Early Stages of Diabetic Retinopathy

TL;DR: This new hypothesis offers new insight into the pathogenesis of diabetic retinopathy, and offers novel targets to inhibit the ocular disease.